If you need more anticipation US2.3b, page-37

Maybe the dots don't join, though PYC have a collaboration with Sue Fletcher at Murdoch Uni, who with Steve Wilton originally developed Sarepta's commerical drug Exondys 51. Fletcher's work gets funding from Sarepta and from memory Sarepta has some rights over the research.
from PYC's HY report:
Also, there has been further encouraging progress in the collaboration with Murdoch University on oligonucleotide delivery. A round of intravenous animal model experiments has shown preliminary signs of efficacy, and importantly, lack of toxicity, in delivery of exon-skipping oligonucleotides in models of both Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) to muscles in a range of locations (including cardiac, diaphragm and tibia). Excitingly, evidence has been seen for increased levels of the dystrophin protein following treatment with FPP-delivered exon-skipping oligonucleotides.
............................
DYOR